Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 infections

被引:76
|
作者
Andeweg, Stijn P. [1 ]
de Gier, Brechje [1 ]
Eggink, Dirk [1 ]
van den Ende, Caroline [1 ]
van Maarseveen, Noortje [2 ,3 ]
Ali, Lubna [2 ]
Vlaemynck, Boris [4 ]
Schepers, Raf [4 ]
Hahne, Susan J. M. [1 ]
Reusken, Chantal B. E. M. [1 ]
de Melker, Hester E. [1 ]
van den Hof, Susan [1 ]
Knol, Mirjam J. [1 ]
机构
[1] Ctr Infect Dis Control, Natl Inst Publ Hlth & Environm RIVM, Bilthoven, Netherlands
[2] Saltro Diagnost Ctr Primary Care, Utrecht, Netherlands
[3] Univ Med Ctr Utrecht, Dept Med Microbiol, Utrecht, Netherlands
[4] SYNLAB, Heppignies, Belgium
关键词
D O I
10.1038/s41467-022-31838-8
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The protection of COVID-19 vaccines against emerging variants needs to be monitored. Here, the authors use community testing data from the Netherlands and find that protection against infection by Omicron subvariants BA.1 and 2 is low and that booster vaccines considerably but temporarily increase protection. Given the emergence of the SARS-CoV-2 Omicron BA.1 and BA.2 variants and the roll-out of booster COVID-19 vaccination, evidence is needed on protection conferred by primary vaccination, booster vaccination and previous SARS-CoV-2 infection by variant. We employed a test-negative design on S-gene target failure data from community PCR testing in the Netherlands from 22 November 2021 to 31 March 2022 (n = 671,763). Previous infection, primary vaccination or both protected well against Delta infection. Protection against Omicron BA.1 infection was much lower compared to Delta. Protection was similar against Omicron BA.1 compared to BA.2 infection after previous infection, primary and booster vaccination. Higher protection was observed against all variants in individuals with both vaccination and previous infection compared with either one. Protection against all variants decreased over time since last vaccination or infection. We found that primary vaccination with current COVID-19 vaccines and previous SARS-CoV-2 infections offered low protection against Omicron BA.1 and BA.2 infection. Booster vaccination considerably increased protection against Omicron infection, but decreased rapidly after vaccination.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Long term anti-SARS-CoV-2 antibody kinetics and correlate of protection against Omicron BA.1/BA.2 infection
    Javier Perez-Saez
    María-Eugenia Zaballa
    Julien Lamour
    Sabine Yerly
    Richard Dubos
    Delphine S. Courvoisier
    Jennifer Villers
    Jean-François Balavoine
    Didier Pittet
    Omar Kherad
    Nicolas Vuilleumier
    Laurent Kaiser
    Idris Guessous
    Silvia Stringhini
    Andrew S. Azman
    Nature Communications, 14
  • [32] Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA.1, BA.2, and BA.5
    Tomokazu Tamura
    Daichi Yamasoba
    Yoshitaka Oda
    Jumpei Ito
    Tomoko Kamasaki
    Naganori Nao
    Rina Hashimoto
    Yoichiro Fujioka
    Rigel Suzuki
    Lei Wang
    Hayato Ito
    Yukie Kashima
    Izumi Kimura
    Mai Kishimoto
    Masumi Tsuda
    Hirofumi Sawa
    Kumiko Yoshimatsu
    Yuki Yamamoto
    Tetsuharu Nagamoto
    Jun Kanamune
    Yutaka Suzuki
    Yusuke Ohba
    Isao Yokota
    Keita Matsuno
    Kazuo Takayama
    Shinya Tanaka
    Kei Sato
    Takasuke Fukuhara
    Communications Biology, 6
  • [33] Omicron BA.1 and BA.2 variants increase the interactions of SARS-CoV-2 with ACE2
    Golcuk, Mert
    Yildiz, Ahmet
    Gur, Mert
    JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2022, 117
  • [34] Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3
    Arora, Prerna
    Zhang, Lu
    Rocha, Cheila
    Sidarovich, Anzhalika
    Kempf, Amy
    Schulz, Sebastian
    Cossmann, Anne
    Manger, Bernhard
    Baier, Eva
    Tampe, Bjoern
    Moerer, Onnen
    Dickel, Steffen
    Dopfer-Jablonka, Alexandra
    Jaeck, Hans-Martin
    Behrens, Georg M. N.
    Winkler, Martin S.
    Poehlmann, Stefan
    Hoffmann, Markus
    LANCET INFECTIOUS DISEASES, 2022, 22 (06): : 766 - 767
  • [35] Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA.1, BA.2, and BA.5
    Tamura, Tomokazu
    Yamasoba, Daichi
    Oda, Yoshitaka
    Ito, Jumpei
    Kamasaki, Tomoko
    Nao, Naganori
    Hashimoto, Rina
    Fujioka, Yoichiro
    Suzuki, Rigel
    Wang, Lei
    Ito, Hayato
    Kashima, Yukie
    Kimura, Izumi
    Kishimoto, Mai
    Tsuda, Masumi
    Sawa, Hirofumi
    Yoshimatsu, Kumiko
    Yamamoto, Yuki
    Nagamoto, Tetsuharu
    Kanamune, Jun
    Suzuki, Yutaka
    Ohba, Yusuke
    Tabata, Kaori
    Yokota, Isao
    Matsuno, Keita
    Takayama, Kazuo
    Tanaka, Shinya
    Sato, Kei
    Fukuhara, Takasuke
    COMMUNICATIONS BIOLOGY, 2023, 6 (01)
  • [36] Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS)
    Maeda, Haruka
    Saito, Nobuo
    Igarashi, Ataru
    Ishida, Masayuki
    Terada, Mayumi
    Ito, Takayasu
    Ikeda, Hideko
    Kamura, Hiroshi
    Motohashi, Iori
    Kimura, Yuya
    Komino, Masaru
    Arai, Hiromi
    Kuwamitsu, Osamu
    Akuzawa, Nobuhiro
    Sando, Eiichiro
    Morikawa, Toru
    Imura, Haruki
    Inoue, Hiroki
    Hayakawa, Tomoichiro
    Teshigahara, Osamu
    Ohara, Yasuji
    Suzuki, Motoi
    Morimoto, Konosuke
    EXPERT REVIEW OF VACCINES, 2023, 22 (01) : 288 - 298
  • [37] Virological Characteristics of Five SARS-CoV-2 Variants, Including Beta, Delta and Omicron BA.1, BA.2, BA.5
    Zeng, Yan
    Xia, Fei
    Guo, Changfu
    Hu, Chunxia
    Li, Yuwei
    Wang, Xiang
    Wu, Qin
    Chen, Zhuo
    Lu, Jia
    Wang, Zejun
    VIRUSES-BASEL, 2023, 15 (12):
  • [38] Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2
    Evans, John P.
    Zeng, Cong
    Qu, Panke
    Faraone, Julia
    Zheng, Yi-Min
    Carlin, Claire
    Bednash, Joseph S.
    Zhou, Tongqing
    Lozanski, Gerard
    Mallampalli, Rama
    Saif, Linda J.
    Oltz, Eugene M.
    Mohler, Peter J.
    Xu, Kai
    Gumina, Richard J.
    Liu, Shan-Lu
    CELL HOST & MICROBE, 2022, 30 (08) : 1093 - +
  • [39] Two human monoclonal SARS-CoV-2 antibodies that maintain neutralizing potency against the SARS-CoV-2 Omicron BA.1 and BA.2 variants
    Zheng, Qianqian
    Duan, Liangwei
    Jiang, Zhihua
    Gu, Tingxuan
    Zhang, Bojie
    Li, Jiaoyang
    Zhang, Yang
    Zhang, Shiyu
    Liang, Yinming
    Wang, Hui
    GENES & DISEASES, 2023, 10 (03) : 664 - 667
  • [40] SARS-CoV-2 Omicron variants BA.1 and BA.2 both show similarly reduced disease severity of COVID-19 compared to Delta, Germany, 2021 to 2022
    Sievers, Claudia
    Zacher, Benedikt
    Ullrich, Alexander
    Huska, Matthew
    Fuchs, Stephan
    Buda, Silke
    Haas, Walter
    Diercke, Michaela
    an der Heiden, Matthias
    Kroeger, Stefan
    EUROSURVEILLANCE, 2022, 27 (22)